WST has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
WST has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2025-04-13), West Pharmaceutical Services's share price is $210.70. West Pharmaceutical Services's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $3.76. Hence, West Pharmaceutical Services's Price-to-Free-Cash-Flow Ratio for today is 56.08.
The historical rank and industry rank for West Pharmaceutical Services's Price-to-Free-Cash-Flow or its related term are showing as below:
During the past 13 years, West Pharmaceutical Services's highest Price-to-Free-Cash-Flow Ratio was 133.69. The lowest was 37.04. And the median was 65.06.
West Pharmaceutical Services's Free Cash Flow per Share for the three months ended in Dec. 2024 was $1.16. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $3.76.
During the past 12 months, the average Free Cash Flow per Share Growth Rate of West Pharmaceutical Services was -31.90% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -4.70% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 6.20% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 22.20% per year.
During the past 13 years, West Pharmaceutical Services's highest 3-Year average Free Cash Flow per Share Growth Rate was 93.40% per year. The lowest was -40.80% per year. And the median was 12.50% per year.
The historical data trend for West Pharmaceutical Services's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
West Pharmaceutical Services Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial |
![]() |
![]() |
72.03 | 108.24 | 40.60 | 63.96 | 87.35 |
West Pharmaceutical Services Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
63.96 | 76.91 | 68.91 | 69.13 | 87.35 |
For the Medical Instruments & Supplies subindustry, West Pharmaceutical Services's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, West Pharmaceutical Services's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where West Pharmaceutical Services's Price-to-Free-Cash-Flow falls into.
West Pharmaceutical Services's Price-to-Free-Cash-Flow ratio for today is calculated as
Price-to-Free-Cash-Flow Ratio | = | Share Price | / | Free Cash Flow per Share (TTM) |
= | 210.70 | / | 3.757 | |
= | 56.08 |
West Pharmaceutical Services's Share Price of today is $210.70.
West Pharmaceutical Services's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.76.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price-to-Free-Cash-Flow Ratio | = | Market Cap | / | Free Cash Flow |
West Pharmaceutical Services (NYSE:WST) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Thank you for viewing the detailed overview of West Pharmaceutical Services's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Charles Witherspoon | officer: VP & Treasurer | 530 HERMAN O WEST DRIVE, EXTON PA 19341 |
Eric Mark Green | officer: Chief Executive Officer | 530 HERMAN O. WEST DRIVE, EXTON PA 19341 |
Silji Abraham | officer: Chief Digital & Trans Officer | 5000 TOWN CENTER, U, SOUTHFIELD MI 48075 |
Thomas W Hofmann | director | FIVE RADNOR CORPORATE CENTER, SUITE 500, RADNOR PA 19087 |
Chad Winters | officer: VP, CAO & Controller | 530 HERMAN O. WEST DRIVE, EXTON PA 19341 |
Annette F Favorite | officer: Sr. VP Human Resources Officer | 530 HERMAN O. WEST DRIVE, EXTON PA 19341 |
Cindy Reiss-clark | officer: Senior Vice President | 530 HERMAN O. WEST DRIVE, EXTON PA 19341-1147 |
Quintin J Lai | officer: VP Corp Development & Strategy | 530 HERMAN 0. WEST DRIVE, EXTON PA 19341 |
Bernard Birkett | officer: Sr VP, CFO & Treasurer | 1600 WEST MERIT PARKWAY, SOUTH JORDAN UT 84095 |
Stephen H Lockhart | director | C/O NATIONAL RESEARCH CORPORATION, 1245 Q STREET, LINCOLN NE 68508 |
Molly Joseph | director | 9209 GRAND SUMMIT BLVD, DRIPPING SPRINGS TX 78620 |
Kimberly Banks Mackay | officer: SVP, GC & Corporate Secretary | 530 HERMAN O. WEST DRIVE, EXTON PA 19341 |
George Lloyd Miller | officer: Sr. VP, GC & Corp. Sec. | 530 HERMAN O. WEST DRIVE, EXTON PA 19341 |
David A Montecalvo | officer: SVP, Glob Ops and Supply Chain | 530 HERMAN O. WEST DRIVE, EXTON PA 19341 |
Robert F Friel | director | 940 WINTER STREET, WALTHAM MA 02451 |
From GuruFocus
By PRNewswire • 01-22-2025
By PRNewswire • 01-06-2025
By GuruFocus News • 02-14-2025
By GuruFocus News • 02-13-2025
By GuruFocus News • 12-14-2024
By GuruFocus News • 02-14-2025
By PRNewswire • 02-13-2025
By GuruFocus News • 03-03-2025
By PRNewswire • 01-30-2025
By GuruFocus News • 02-13-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.